Biodesix Strengthens Partnership with Bio-Rad for Advanced Testing
Partnership Expansion Between Biodesix and Bio-Rad
Biodesix, Inc. (NYSE: BDSX), a prominent diagnostics solutions company, has recently strengthened its collaboration with Bio-Rad Laboratories. This expanded partnership focuses on developing and validating advanced in vitro diagnostic assays aimed at enhancing the detection of genomic markers in oncology applications. Utilizing Bio-Rad's renowned Droplet Digital™ PCR technology on its QX600 platform, Biodesix aims to create highly sensitive assays tailored for precise cancer diagnostics.
Cutting-Edge Assays for Oncology Applications
The initial assay being worked on under this partnership is the ddPLEX ESR1 Mutation Detection Assay. This assay holds significant potential as ESR1 testing is critical for managing HR+/HER2- advanced breast cancer. The technologies being utilized will allow for accurate detection and quantification of various ESR1 mutations within circulating tumor DNA (ctDNA) samples, which is vital for improving patient outcomes.
Supporting Biopharma and Clinical Clients
Once the validation process is complete, the ESR1 mutation assay will be available as a test service at Biodesix' accredited laboratory, which is CLIA-CAP certified. This offering aims to support biopharmaceutical companies in developing targeted therapies and assist clinical practitioners in monitoring cancer treatments effectively. Moreover, Biodesix plans to work closely with the Centers for Medicare & Medicaid Services (CMS) to explore reimbursement options for the assay, emphasizing its commitment to accessible healthcare innovations.
Leadership Insights on the Partnership
Scott Hutton, the CEO of Biodesix, expressed enthusiasm regarding the expanded partnership. "The emergence of ESR1 mutations as significant biomarkers has transformed the landscape of breast cancer treatment. We are eager to enhance our capabilities through this collaboration, ensuring rapid and sensitive assay development that meets clinical demands and paves the way for personalized medicine," he stated.
Ongoing Collaboration in the Oncology Field
Steve Kulisch, VP of Product Management at Bio-Rad Laboratories, commented on the long-standing relationship with Biodesix. He noted that their previous collaborations have effectively addressed both clinical and research applications, particularly in non-small cell lung cancer diagnostics. The advancement of the ddPLEX ESR1 kits represents another step forward in their mission to improve biomarker detection and patient outcomes for advanced breast cancer.
Upcoming Events and Presentations
Biodesix and Bio-Rad will be featuring their collaborative efforts and R&D visions at an upcoming conference. They will detail their partnership at the AMP conference, scheduled for mid-November in Boston, MA. This event will provide insights into their commercial strategies and future developments in clinical research.
About Biodesix
Biodesix is devoted to advancing diagnostic solutions that enhance patient care and clinical outcomes. Their products, such as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, are designed to assist healthcare providers in making informed decisions quickly. Furthermore, Biodesix Development Services empower top biopharmaceutical and life sciences organizations by providing essential support for developing innovative diagnostic tools and therapeutic solutions.
Contact Information for Biodesix
Media Inquiries:
Natalie St. Denis, Director of Corporate Communications
Email: natalie.stdenis@biodesix.com
Phone: (720) 925-9285
Investor Relations:
Chris Brinzey, Partner at ICR
Email: chris.brinzey@icrhealthcare.com
Phone: (339) 970-2843
Frequently Asked Questions
What is the focus of the partnership between Biodesix and Bio-Rad?
The partnership focuses on developing advanced diagnostic assays for oncology applications using Bio-Rad's ddPCR technology.
What is the significance of the ESR1 Mutation Detection Assay?
This assay is crucial for detecting mutations in HR+/HER2- advanced breast cancer, thereby aiding in patient treatment management.
How will the ESR1 assay benefit biopharma clients?
It will support biopharma clients in developing targeted therapies and monitoring treatment effectiveness.
What are the future plans for Biodesix regarding the ESR1 assay?
Biodesix plans to validate the assay and seek reimbursement options through CMS to ensure accessibility for patients.
What are Biodesix's main products?
Biodesix offers Nodify Lung for nodule risk assessment and IQLung for cancer treatment guidance, improving decision-making in clinical settings.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.